探讨研究IL-27与N-乙酰半光氨酸(NAC)对博来霉素诱导的小鼠肺纤维化模型影响；

经小鼠支气管内注入博来霉素建立模型后，分为正常组(A组)、博莱霉素模型(BLM)组(B组)、BLM+IL-27组(C组)、BLM+NAC组(D组)，各组分别于7、14、28 d处死小鼠5只，取肺组织行HE染色及Masson染色，行肺组织肺泡炎、肺纤维化评分、羟脯氨酸含量测定并对比；

7 d肺泡炎评分：A组(1.00±0.00)，B组(3.47±0.23)，C组(2.17±0.13)，D组(2.89±0.29)；14 d肺泡炎评分：A组(1.00±0.00)，B组(2.94±0.31)，C组(1.92±0.16)，D组(2.48±0.19)；28 d肺泡炎评分：A组(1.00±0.00)，B组(1.97±0.19)，C组(1.38±0.18)，D组(1.65±0.17)。7 d肺纤维化评分：A组(1.00±0.00)，B组(1.82±0.22)，C组(1.21±0.13)，D组(1.51±0.26)；14 d肺纤维化评分：A组(1.00±0.00)，B组(2.64±0.32)，C组(1.95±0.15)，D组(2.13±0.16)；28 d肺纤维化评分：A组(1.00±0.00)，B组(3.48±0.14)，C组(2.17±0.17)，D组(2.96±0.18)；7 d肺组织羟脯胺酸含量：A组(143.19±4.09)，B组(281.83±8.31)，C组(207.81±5.29)，D组(231.49±3.97)；14 d肺组织羟脯胺酸含量：A组(147.81±8.91)，B组(317.63±6.30)，C组(253.86±4.91)，D组(289.73±5.09)；14 d肺组织羟脯胺酸含量：A组(141.82±7.28)，B组(381.97±5.49)，C组(303.81±4.92)，D组(358.29±7.38)；各组差异具有统计学意义。

NAC、IL-27均有抑制博来霉素诱导的小鼠肺纤维化进程的作用，但IL-27干预组小鼠肺泡炎评分、肺肺纤维化评分、羟脯胺酸含量均低于NAC干预组。故IL-27抑制肺纤维化进程的疗效优于NAC。

To compare the effects of interleukin (IL)-27 and N-acetylcysteine (NAC) on bleomycin-induced pulmonary fibrosis in mice.

Mice models were established by endobronchial injection of bleomycin (BLM). The normal healthy mice were taken as group A, the mice receiving only endobronchial injection of BLM were taken as group B, the mice receiving endobronchial injection of BLM+ IL-27 were taken as group C, and the mice receiving endobronchial injection of BLM+ NAC were taken as group D. Every 5 mice were executed in each group respectively at 7, 14, and 28 days after treatment. Then HE staining and Masson staining were performed on the lung tissues, and alveolitis scoring, pulmonary fibrosis scoring, and hydroxyproline content determination of the lung tissues were made and compared.

The 7-day alveolitis scores were (1.00±0.00) in group A, (3.47±0.23) in group B, (2.17±0.13) in group C, and (2.89±0.29) in group D. The 14-day alveolitis scores were (1.00±0.00) in group A, (2.94±0.31) in group B, (1.92±0.16) in group C, and (2.48±0.19) group D. And the 28-day alveolitis scores were (1.00±0.00) group A, (1.97±0.19) in group B, (1.38±0.18) in group C, and (1.65±0.17) in group D. The 7-day pulmonary fibrosis scores were (1.00±0.00) in group A, (1.82±0.22) in group B, (1.21±0.13) in group C, and (1.51±0.26) in group D. The 14-day pulmonary fibrosis scores were (1.00±0.00) in group A, (2.64±0.32) in group B, (1.95±0.15) in group C, and (2.13±0.16) in group D. And the 28-day pulmonary fibrosis scores were (1.00±0.00) in group A, (3.48±0.14) in group B, (2.17±0.17) in group C, and (2.96±0.18) in group D. The 7-day lung tissue hydroxyproline contents were (143.19±4.09) in group A, (281.83±8.31) in group B, (207.81±5.29) in group C, and (231.49±3.97) in group D. The 14-day lung tissue hydroxyproline contents were (147.81±8.91) in group A, (317.63±6.30) in group B, (253.86±4.91) in group C, and (289.73±5.09) in group D. And 28-day lung tissue hydroxyproline contents were (141.82±7.28) in group A, (381.97±5.49) in group B, (303.81±4.92) in group C, and (358.29±7.38) in group D. The differences among the groups were statistically significant.

NAC and IL-27 have inhibitory effects on the bleomycin-induced pulmonary fibrosis in mice. However, the alveolitis scores, pulmonary fibrosis scores and hydroxyproline contents in the IL-27 intervention groups were lower than those in the NAC intervention group. Therefore, IL-27 is superior to NAC in inhibiting pulmonary fibrosis.